NO323107B1 - Anvendelse av fotosensibiliseringsmiddel for fremstilling av medikament for anvendelse i behandling for a odelegge eller skade et omrade av neovaskularisering - Google Patents
Anvendelse av fotosensibiliseringsmiddel for fremstilling av medikament for anvendelse i behandling for a odelegge eller skade et omrade av neovaskularisering Download PDFInfo
- Publication number
- NO323107B1 NO323107B1 NO19952004A NO952004A NO323107B1 NO 323107 B1 NO323107 B1 NO 323107B1 NO 19952004 A NO19952004 A NO 19952004A NO 952004 A NO952004 A NO 952004A NO 323107 B1 NO323107 B1 NO 323107B1
- Authority
- NO
- Norway
- Prior art keywords
- light
- photosensitizer
- treatment
- bpd
- animal
- Prior art date
Links
- 239000003504 photosensitizing agent Substances 0.000 title claims abstract description 67
- 239000003814 drug Substances 0.000 title claims description 18
- 206010029113 Neovascularisation Diseases 0.000 title claims description 16
- 230000006378 damage Effects 0.000 title claims description 16
- 229940079593 drug Drugs 0.000 title description 13
- 238000002360 preparation method Methods 0.000 title description 3
- 241001465754 Metazoa Species 0.000 claims abstract description 44
- 238000002428 photodynamic therapy Methods 0.000 claims abstract description 14
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 claims description 10
- 229960004293 porfimer sodium Drugs 0.000 claims description 10
- 150000004032 porphyrins Chemical class 0.000 claims description 9
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 230000005284 excitation Effects 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 2
- SURLGNKAQXKNSP-DBLYXWCISA-N chlorin Chemical compound C\1=C/2\N/C(=C\C3=N/C(=C\C=4NC(/C=C\5/C=CC/1=N/5)=CC=4)/C=C3)/CC\2 SURLGNKAQXKNSP-DBLYXWCISA-N 0.000 claims 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 claims 2
- BBNQQADTFFCFGB-UHFFFAOYSA-N purpurin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC(O)=C3C(=O)C2=C1 BBNQQADTFFCFGB-UHFFFAOYSA-N 0.000 claims 2
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- DZVCFNFOPIZQKX-LTHRDKTGSA-M merocyanine Chemical compound [Na+].O=C1N(CCCC)C(=O)N(CCCC)C(=O)C1=C\C=C\C=C/1N(CCCS([O-])(=O)=O)C2=CC=CC=C2O\1 DZVCFNFOPIZQKX-LTHRDKTGSA-M 0.000 claims 1
- 238000002347 injection Methods 0.000 abstract description 46
- 239000007924 injection Substances 0.000 abstract description 46
- 238000000034 method Methods 0.000 abstract description 22
- 206010028980 Neoplasm Diseases 0.000 description 43
- 210000001519 tissue Anatomy 0.000 description 31
- 241000699670 Mus sp. Species 0.000 description 23
- 150000001875 compounds Chemical class 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 230000005855 radiation Effects 0.000 description 9
- 206010034972 Photosensitivity reaction Diseases 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 5
- 206010039509 Scab Diseases 0.000 description 5
- -1 chlorine e6) Chemical class 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000002165 photosensitisation Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- SIEXFRDYNDREBM-UHFFFAOYSA-N 2-[[2-[7-carboxy-3-(2-carboxyethyl)-17-ethenyl-12-ethyl-2,8,13,18-tetramethyl-2,3,23,24-tetrahydroporphyrin-5-yl]acetyl]amino]butanedioic acid Chemical compound N1C2=C(C)C(C=C)=C1C=C(N1)C(C)=C(CC)C1=CC(C(C)=C1C(O)=O)=NC1=C(CC(=O)NC(CC(O)=O)C(O)=O)C(C(CCC(O)=O)C1C)=NC1=C2 SIEXFRDYNDREBM-UHFFFAOYSA-N 0.000 description 4
- MHIITNFQDPFSES-UHFFFAOYSA-N 25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1(25),2,4,6,8(27),9,11,13,15,17,19,21,23-tridecaene Chemical class N1C(C=C2C3=CC=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 MHIITNFQDPFSES-UHFFFAOYSA-N 0.000 description 4
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 208000007578 phototoxic dermatitis Diseases 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- XFHNUTUVALSHOS-UHFFFAOYSA-N 21-hydroxy-5,10,15,20-tetraphenyl-23H-porphyrin-2,3,7-triol Chemical compound Oc1cc2nc1c(-c1ccccc1)c1c(O)c(O)c(c(-c3ccccc3)c3ccc(n3)c(-c3ccccc3)c3ccc([nH]3)c2-c2ccccc2)n1O XFHNUTUVALSHOS-UHFFFAOYSA-N 0.000 description 3
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 3
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical class CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 3
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 3
- 238000011765 DBA/2 mouse Methods 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 229960002749 aminolevulinic acid Drugs 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 150000004035 chlorins Chemical class 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000009931 harmful effect Effects 0.000 description 3
- 230000036211 photosensitivity Effects 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229950003776 protoporphyrin Drugs 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000004036 bacteriochlorins Chemical class 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 230000037368 penetrate the skin Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940109328 photofrin Drugs 0.000 description 2
- 231100000018 phototoxicity Toxicity 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- OYINILBBZAQBEV-UWJYYQICSA-N (17s,18s)-18-(2-carboxyethyl)-20-(carboxymethyl)-12-ethenyl-7-ethyl-3,8,13,17-tetramethyl-17,18,22,23-tetrahydroporphyrin-2-carboxylic acid Chemical compound N1C2=C(C)C(C=C)=C1C=C(N1)C(C)=C(CC)C1=CC(C(C)=C1C(O)=O)=NC1=C(CC(O)=O)C([C@@H](CCC(O)=O)[C@@H]1C)=NC1=C2 OYINILBBZAQBEV-UWJYYQICSA-N 0.000 description 1
- ATNMPCPGYQSWBN-REOHCLBHSA-N (3s)-3-amino-4-chloro-4-oxobutanoic acid Chemical compound ClC(=O)[C@@H](N)CC(O)=O ATNMPCPGYQSWBN-REOHCLBHSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006802 Burns second degree Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 238000005698 Diels-Alder reaction Methods 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- QCWPXJXDPFRUGF-UHFFFAOYSA-N N1C=2C=C(N=3)C=CC=3C=C(N3)C=CC3=CC(=N3)C=CC3=CC1=CC=2C1=CC=CC=C1 Chemical compound N1C=2C=C(N=3)C=CC=3C=C(N3)C=CC3=CC(=N3)C=CC3=CC1=CC=2C1=CC=CC=C1 QCWPXJXDPFRUGF-UHFFFAOYSA-N 0.000 description 1
- 206010067193 Naevus flammeus Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 208000009608 Papillomavirus Infections Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000006787 Port-Wine Stain Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000017168 chlorine Nutrition 0.000 description 1
- 125000001309 chloro group Chemical class Cl* 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 208000002026 familial multiple nevi flammei Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 208000002409 gliosarcoma Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000000079 pharmacotherapeutic effect Effects 0.000 description 1
- 238000005362 photophoresis Methods 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 150000004033 porphyrin derivatives Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Photoreceptors In Electrophotography (AREA)
- Radiation-Therapy Devices (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Adhesives Or Adhesive Processes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97954692A | 1992-11-20 | 1992-11-20 | |
| PCT/CA1993/000490 WO1994012239A1 (en) | 1992-11-20 | 1993-11-17 | Method of activating photosensitive agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO952004D0 NO952004D0 (no) | 1995-05-19 |
| NO952004L NO952004L (no) | 1995-07-11 |
| NO323107B1 true NO323107B1 (no) | 2007-01-02 |
Family
ID=25526957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19952004A NO323107B1 (no) | 1992-11-20 | 1995-05-19 | Anvendelse av fotosensibiliseringsmiddel for fremstilling av medikament for anvendelse i behandling for a odelegge eller skade et omrade av neovaskularisering |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US5705518A (ja) |
| EP (2) | EP0947222B1 (ja) |
| JP (1) | JP3146008B2 (ja) |
| KR (1) | KR100230588B1 (ja) |
| AT (2) | ATE189966T1 (ja) |
| AU (1) | AU679016B2 (ja) |
| CA (1) | CA2149636C (ja) |
| DE (3) | DE69334009T2 (ja) |
| DK (2) | DK0680365T3 (ja) |
| ES (2) | ES2148132T3 (ja) |
| FI (1) | FI952436A (ja) |
| GR (1) | GR3033362T3 (ja) |
| HK (1) | HK1025059A1 (ja) |
| HU (1) | HU224722B1 (ja) |
| IL (1) | IL107676A (ja) |
| NO (1) | NO323107B1 (ja) |
| PH (1) | PH31688A (ja) |
| PL (1) | PL172480B1 (ja) |
| PT (2) | PT680365E (ja) |
| WO (1) | WO1994012239A1 (ja) |
| ZA (1) | ZA938710B (ja) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6710066B2 (en) * | 1989-07-28 | 2004-03-23 | Queen's University At Kingston | Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins |
| US20020058008A1 (en) * | 1989-07-28 | 2002-05-16 | Kennedy James C. | Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins |
| US20040110819A1 (en) * | 1991-10-28 | 2004-06-10 | Queen's University At Kingston | Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins |
| US6890555B1 (en) * | 1992-02-05 | 2005-05-10 | Qlt, Inc. | Liposome compositions of porphyrin photosensitizers |
| US5368841A (en) * | 1993-02-11 | 1994-11-29 | The General Hospital Corporation | Photodynamic therapy for the destruction of the synovium in the treatment of rheumatoid arthritis and the inflammatory arthritides |
| JP3565442B2 (ja) * | 1993-04-22 | 2004-09-15 | 新日本石油化学株式会社 | 哺乳類の関節炎の診断剤および／または治療剤 |
| US5798349A (en) | 1994-03-14 | 1998-08-25 | The General Hospital Corporation | Use of green porphyrins to treat neovasculature in the eye |
| JP2961074B2 (ja) | 1995-09-06 | 1999-10-12 | 明治製菓株式会社 | 光化学療法用の新生血管閉塞剤 |
| AU723016B2 (en) * | 1995-11-06 | 2000-08-17 | New York Blood Center, Inc., The | Viral inactivation treatment of red blood cells using phthalocyanines and red light |
| JP3845469B2 (ja) | 1996-02-21 | 2006-11-15 | 明治製菓株式会社 | 眼底の新生血管の閉塞に用いる投与剤 |
| GB9700396D0 (en) * | 1997-01-10 | 1997-02-26 | Photocure As | Photochemotherapeutic compositions |
| US6008889A (en) * | 1997-04-16 | 1999-12-28 | Zeng; Haishan | Spectrometer system for diagnosis of skin disease |
| US6103706A (en) * | 1997-04-29 | 2000-08-15 | New York Blood Center, Inc. | Methods for treating viral infections |
| US6010890A (en) * | 1997-04-29 | 2000-01-04 | New York Blood Center, Inc. | Method for viral inactivation and compositions for use in same |
| DE19721489A1 (de) * | 1997-05-23 | 1998-11-26 | Tibor Dr Nagypal | System zur photodynamischen Behandlung von Lebewesen, deren Organen und/oder Geweben |
| US6128525A (en) * | 1997-07-29 | 2000-10-03 | Zeng; Haishan | Apparatus and method to monitor photodynamic therapy (PDT) |
| US6096066A (en) * | 1998-09-11 | 2000-08-01 | Light Sciences Limited Partnership | Conformal patch for administering light therapy to subcutaneous tumors |
| US6117862A (en) * | 1998-10-09 | 2000-09-12 | Qlt, Inc. | Model and method for angiogenesis inhibition |
| IL126953A0 (en) | 1998-11-08 | 1999-09-22 | Yeda Res & Dev | Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives |
| US6454789B1 (en) * | 1999-01-15 | 2002-09-24 | Light Science Corporation | Patient portable device for photodynamic therapy |
| US6602274B1 (en) * | 1999-01-15 | 2003-08-05 | Light Sciences Corporation | Targeted transcutaneous cancer therapy |
| CA2356532A1 (en) * | 1999-01-15 | 2000-07-20 | Light Sciences Corporation | Noninvasive vascular therapy |
| JP2002534483A (ja) * | 1999-01-15 | 2002-10-15 | ライト サイエンシーズ コーポレイション | 代謝性骨障害または骨転移のための治療的組成物 |
| US20020022032A1 (en) * | 1999-04-23 | 2002-02-21 | Curry Patrick Mark | Immuno-adjuvant PDT treatment of metastatic tumors |
| US20030114434A1 (en) * | 1999-08-31 | 2003-06-19 | James Chen | Extended duration light activated cancer therapy |
| EP1218017B1 (en) * | 1999-09-24 | 2005-11-16 | Vasogen Ireland Limited | Combination of a statin and ex-vivo treated blood for treating atherosclerosis |
| US7897140B2 (en) | 1999-12-23 | 2011-03-01 | Health Research, Inc. | Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents |
| WO2001051087A2 (en) * | 2000-01-12 | 2001-07-19 | Light Sciences Corporation | Novel treatment for eye disease |
| CN100398153C (zh) * | 2000-03-24 | 2008-07-02 | 诺瓦提斯公司 | 抗血管生成药与光敏剂的联合制药用途 |
| US6454790B1 (en) * | 2000-07-21 | 2002-09-24 | Ceramoptec Industries, Inc. | Treatment for Barrett's syndrome |
| US7193706B2 (en) * | 2000-08-02 | 2007-03-20 | Arizona Board Of Regents, Acting On Behalf Of Arizona State University | Computer interfaced scanning fluorescence lifetime microscope applied to directed evolution |
| AU2002346661A1 (en) * | 2001-12-03 | 2003-06-17 | The Regents Of The University Of California | Photodynamic therapy for the treatment of epilepsy |
| DE10162712A1 (de) * | 2001-12-19 | 2003-07-17 | Blutspendienst Der Landesverba | Verfahren zur Inaktivierung von Bakterien und Leukozyten in Blut oder Blutprodukten |
| JP2005527493A (ja) * | 2002-01-23 | 2005-09-15 | ライト サイエンシーズ コーポレイション | 光線力学療法のためのシステムおよび方法 |
| US7041121B1 (en) * | 2002-01-31 | 2006-05-09 | Medtronicvidamed, Inc. | Apparatus for treating prostate cancer and method for same |
| DE60328496D1 (en) | 2002-06-27 | 2009-09-03 | Health Research Inc | Fluorinierte chlorin und bacteriochlorin photosensitizer für fotodynamische therapie |
| CA2500877A1 (en) * | 2002-10-03 | 2004-04-15 | Light Sciences Corporation | Excitation of photoreactive compounds in eye tissue |
| US7780992B2 (en) * | 2002-12-08 | 2010-08-24 | Tareq Abduljalil Albahri | Antiviral medicament |
| US20040220167A1 (en) * | 2003-05-02 | 2004-11-04 | Nasrollah Samiy | Methods of treating neuralgic pain |
| US20060020033A1 (en) * | 2004-07-21 | 2006-01-26 | Ali Moiin | Method for treating dermatological viral infections |
| US7465312B2 (en) * | 2006-05-02 | 2008-12-16 | Green Medical, Inc. | Systems and methods for treating superficial venous malformations like spider veins |
| WO2007130465A2 (en) * | 2006-05-02 | 2007-11-15 | Green Medical, Inc. | Systems and methods for treating superficial venous malformations like spider veins |
| WO2011059216A2 (ko) * | 2009-11-10 | 2011-05-19 | 가톨릭대학교 산학협력단 | 광감작제가 코팅된 의료용 스텐트 및 이의 제조방법 |
| KR101200210B1 (ko) * | 2009-11-10 | 2012-11-09 | 가톨릭대학교 산학협력단 | 광감작제가 코팅된 의료용 스텐트 및 이의 제조방법 |
| US9211214B2 (en) | 2012-03-21 | 2015-12-15 | Valeant Pharmaceuticals International, Inc | Photodynamic therapy laser |
| GB2517707B (en) | 2013-08-28 | 2020-09-02 | Pci Biotech As | A device for light-induced rupture of endocytic vesicles to effect the delivery of an antigen |
| CN106620893B (zh) | 2015-07-23 | 2021-07-30 | 爱博诺德(北京)医疗科技股份有限公司 | 用于眼部疾病光治疗的材料 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4521762A (en) | 1981-08-27 | 1985-06-04 | Gte Automatic Electric Laboratories, Incorporated | Integratable D/A converter |
| US4649151A (en) * | 1982-09-27 | 1987-03-10 | Health Research, Inc. | Drugs comprising porphyrins |
| US4577636A (en) | 1982-11-23 | 1986-03-25 | The Beth Israel Hospital Association | Method for diagnosis of atherosclerosis |
| DE3472810D1 (en) | 1983-03-07 | 1988-08-25 | Carcedo Jacinto Munoz | Anchorage systems for partition panels |
| US4753958A (en) | 1985-02-07 | 1988-06-28 | University Of Cal | Photochemotherapy of epithelial diseases with derivatives of hematoporphyrins |
| US5095030A (en) * | 1987-01-20 | 1992-03-10 | University Of British Columbia | Wavelength-specific cytotoxic agents |
| US4878891A (en) | 1987-06-25 | 1989-11-07 | Baylor Research Foundation | Method for eradicating infectious biological contaminants in body tissues |
| US4957481A (en) * | 1987-10-01 | 1990-09-18 | U.S. Bioscience | Photodynamic therapeutic technique |
| KR930004775B1 (ko) | 1988-02-01 | 1993-06-05 | 마쓰시다 덴기 산교 가부시기 가이샤 | 3차원 촬상장치 |
| GB8805849D0 (en) * | 1988-03-11 | 1988-04-13 | Efamol Holdings | Porphyrins & cancer treatment |
| US4925736A (en) | 1988-07-06 | 1990-05-15 | Long Island Jewish Medical Center | Topical hematoporphyrin |
| US5028594A (en) * | 1988-12-27 | 1991-07-02 | Naxcor | Use of photodynamic compositions for cytotoxic effects |
| US4935498A (en) | 1989-03-06 | 1990-06-19 | Board Of Regents, The University Of Texas System | Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles |
| CA2012175A1 (en) | 1989-03-31 | 1990-09-30 | Michael W. Berns | Photochemical treatment of blood vessels |
| US4973848A (en) * | 1989-07-28 | 1990-11-27 | J. Mccaughan | Laser apparatus for concurrent analysis and treatment |
| CH684166A5 (it) * | 1990-09-28 | 1994-07-29 | Teclas Tecnologie Laser S A | Apparecchiatura dedicata a radiazione rossa per fotochemioterapia. |
| PT660712E (pt) * | 1992-09-21 | 2001-11-30 | Quadra Logic Tech Inc | Activacao in vivo transdermal de agentes fotossensiveis no sangue |
-
1993
- 1993-11-17 DE DE69334009T patent/DE69334009T2/de not_active Expired - Lifetime
- 1993-11-17 DE DE69327972T patent/DE69327972T2/de not_active Expired - Lifetime
- 1993-11-17 PL PL93309033A patent/PL172480B1/pl unknown
- 1993-11-17 ES ES99201064T patent/ES2148132T3/es not_active Expired - Lifetime
- 1993-11-17 AT AT94900024T patent/ATE189966T1/de active
- 1993-11-17 ES ES94900024T patent/ES2143539T3/es not_active Expired - Lifetime
- 1993-11-17 CA CA002149636A patent/CA2149636C/en not_active Expired - Lifetime
- 1993-11-17 DK DK94900024T patent/DK0680365T3/da active
- 1993-11-17 EP EP99201064A patent/EP0947222B1/en not_active Expired - Lifetime
- 1993-11-17 AU AU54600/94A patent/AU679016B2/en not_active Expired
- 1993-11-17 AT AT99201064T patent/ATE322932T1/de active
- 1993-11-17 WO PCT/CA1993/000490 patent/WO1994012239A1/en active IP Right Grant
- 1993-11-17 KR KR1019950702052A patent/KR100230588B1/ko not_active IP Right Cessation
- 1993-11-17 EP EP94900024A patent/EP0680365B1/en not_active Expired - Lifetime
- 1993-11-17 DK DK99201064T patent/DK0947222T3/da active
- 1993-11-17 HU HU9501489A patent/HU224722B1/hu active IP Right Grant
- 1993-11-17 JP JP51260294A patent/JP3146008B2/ja not_active Expired - Lifetime
- 1993-11-17 PT PT94900024T patent/PT680365E/pt unknown
- 1993-11-17 DE DE0947222T patent/DE947222T1/de active Pending
- 1993-11-17 PT PT99201064T patent/PT947222E/pt unknown
- 1993-11-19 IL IL10767693A patent/IL107676A/en not_active IP Right Cessation
- 1993-11-19 PH PH47297A patent/PH31688A/en unknown
- 1993-11-22 ZA ZA938710A patent/ZA938710B/xx unknown
-
1995
- 1995-02-16 US US08/391,414 patent/US5705518A/en not_active Expired - Lifetime
- 1995-05-19 NO NO19952004A patent/NO323107B1/no not_active IP Right Cessation
- 1995-05-19 FI FI952436A patent/FI952436A/fi not_active Application Discontinuation
- 1995-11-01 US US08/551,471 patent/US5770619A/en not_active Expired - Lifetime
-
2000
- 2000-04-06 HK HK00102119A patent/HK1025059A1/xx not_active IP Right Cessation
- 2000-05-05 GR GR20000401047T patent/GR3033362T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU679016B2 (en) | Method of activating photosensitive agents | |
| CA2144327C (en) | Transcutaneous in vivo activation of photosensitive agents in blood | |
| Lui et al. | Photodynamic therapy in dermatology: recent developments | |
| Messmann et al. | Enhancement of photodynamic therapy with 5-aminolaevulinic acid-induced porphyrin photosensitisation in normal rat colon by threshold and light fractionation studies | |
| Spikes et al. | Photodynamic therapy of tumours and other diseases using porphyrins | |
| Fingar et al. | Drug and light dose dependence of photodynamic therapy: a study of tumor and normal tissue response | |
| Kinsella et al. | Photodynamic therapy in oncology | |
| Mellish et al. | Verteporfin: a milestone in opthalmology and photodynamic therapy | |
| Gomer et al. | Molecular, cellular, and tissue responses following photodynamic therapy | |
| US20070299431A1 (en) | Systems and methods for treating superficial venous malformations like spider veins | |
| US20040147501A1 (en) | Photodynamic therapy | |
| KR20060126470A (ko) | 국소 지방 세포 감소용 광선역학 치료법 | |
| Sharma et al. | Mechanisms of photodynamic therapy | |
| US20090062719A1 (en) | Enhanced PhotoDynamic Therapy with Immune System Assist | |
| JP2006514567A (ja) | 発毛 | |
| Rovers et al. | Significantly increased lesion size by using the near‐infrared photosensitizer 5, 10, 15, 20‐tetrakis (m‐hydroxyphenyl) bacteriochlorin in interstitial photodynamic therapy of normal rat liver tissue | |
| Harvey et al. | Killing tumor cells: the effect of photodynamic therapy using mono-L-aspartyl chlorine and NS-398 | |
| Hampton et al. | Photodynamic therapy: a new modality for the treatment of cancer | |
| RU2680220C1 (ru) | Способ фотодинамической терапии злокачественных новообразований в эксперименте | |
| Nyamekye | Vascular and other non-tumour applications of photodynamic therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |